Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study
Journal of Cancer · 2025-07-01 · 16 (10) · 3015-3023
DOI: 10.7150/jca.113815 ↗At a glance
Journal article in Journal of Cancer, published on 2025-07-01. Written by Martin Svaton and 8 co-authors. Institution: Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic. Cited 2 times so far (Crossref). The full text is freely available in PubMed Central.
Topics: Onkologische Pflege
Abstract (original language)
Background
Patients with non-small cell lung cancer (NSCLC) with PD-L1 expression ≥ 50% can be treated with immunotherapy alone or with a combination of immunotherapy and chemotherapy. One of these options is treatment with pembrolizumab (P) with/without chemotherapy (CHT). Meta-analyses from randomized trials suggest a beneficial effect on response rate (RR) or progression free survival (PFS) when using the combination treatment P + CHT compared to P alone, but not on improving overall survival (OS). However, data from real-world clinical practice are insufficient especially in European patients. Regional differences, e.g. in the representation of KRAS mutations between Asian and European patients, could theoretically influence potential differences between P + CHT and P. Therefore, the aim of this study was to compare P + CHT versus P alone in real clinical practice in patients from Central Europe.
Methods
Retrospective data from 8 comprehensive oncology centres in Central Europe were used. All patients with PD-L1 expression ≥ 50% with stage IV NSCLC treated with pembrolizumab in daily practice to June 2024 were included and their data statistically analysed.
Results
In the whole group 793 patients was included in the study - 706 treated with P and 87 with P+ CHT. In this unadjusted sample, we observed significantly higher RR (p
Subjects
Author keywords
Authors and institutions
- Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.
- Department of Lung Cancer and Chest Tumours Maria Sklodowska-Curie National Research Institute of Cancer, Warsaw, Poland.
- Laboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine Pilsen, Charles University, Pilsen, Czech Republic.
- Department of Clinical Oncology, Specialised Hospital of St Zoerardus Zobor, Nitra, Slovakia.
- Department of oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- Department of Respiratory Medicine, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
Cite
APA
Svaton, M., Knetki-Wroblewska, M., Hosek, P., Chowaniecova, G., Spacek, J., Fischer, O., Bilek, O., Hrnciarik, M., & Kauffmann-Guerrero, D. (2025). Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study. Journal of Cancer, 16(10), 3015-3023. https://doi.org/10.7150/jca.113815
Vancouver
Svaton M, Knetki-Wroblewska M, Hosek P, Chowaniecova G, Spacek J, Fischer O, et al. Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study. Journal of Cancer. 2025;16(10):3015-3023. doi:10.7150/jca.113815
BibTeX
@article{Svaton2025,
author = {Svaton, Martin and Knetki-Wroblewska, Magdalena and Hosek, Petr and Chowaniecova, Gabriela and Spacek, Jan and Fischer, Ondrej and Bilek, Ondrej and Hrnciarik, Michal and Kauffmann-Guerrero, Diego},
title = {Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study},
journal = {Journal of Cancer},
year = {2025},
volume = {16},
number = {10},
pages = {3015--3023},
doi = {10.7150/jca.113815}
}
EUVIMED